Naltrexona Destoxican Pentafarma (Naltrexone Hydrochloride)

Naltrexone, the active ingredient in Naltrexona Destoxican Pentafarma, is an opioid antagonist presented as an oral dosage form for oral use. It is employed in the management of alcohol dependence and opioid dependence to reduce cravings and block opioid effects, and is approved for prescription use in the European Union.

GNH USA supplies Naltrexona Destoxican Pentafarma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand.

Naltrexona Destoxican Pentafarma (naltrexone) acts on the opioid system and is indicated for the following conditions: - Alcohol dependence: reduces cravings and supports maintenance of abstinence. - Opioid dependence: blocks opioid receptors to prevent relapse during detoxification. - Alcohol relapse prevention: helps maintain sobriety by diminishing reinforcing effects of alcohol. - Opioid dependence treatment programs: facilitates withdrawal when combined with psychosocial support.

Naltrexona Destoxican Pentafarma may be associated with a range of adverse reactions, which are categorised by frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: transient cranial pain. - Dizziness: sensation of light‑headedness. - Fatigue: feeling of tiredness or reduced energy.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or liver injury. - Severe depression or suicidal thoughts: mood changes requiring immediate medical attention. - Allergic reactions: rash, pruritus, angioedema, or anaphylaxis. - Seizures: rare convulsive episodes.

Before prescribing Naltrexona Destoxican Pentafarma, clinicians should consider the following precautions. - Liver function assessment: evaluate baseline hepatic enzymes and monitor periodically. - Psychiatric monitoring: watch for worsening depression or emergence of suicidal ideation. - Opioid discontinuation: ensure patients are opioid‑free for at least 7–10 days to avoid precipitated withdrawal. - Concomitant opioid use: avoid co‑administration with opioid analgesics, which can cause withdrawal. - Renal impairment: use with caution in patients with severe kidney disease. - Store at below 25°C: keep in the original packaging, protect from moisture and light.

Naltrexona Destoxican Pentafarma can interact with several medicines; interactions are grouped by clinical significance.

Major Interactions (Avoid): - Opioid analgesics (e.g., morphine, oxycodone): may precipitate acute withdrawal. - Disulfiram: combined use can increase risk of hepatotoxicity. - Isoniazid or other hepatotoxic agents: heightened potential for liver injury.

Moderate Interactions (Monitor Closely): - Benzodiazepines: additive central nervous system depression may occur. - Antidepressants (e.g., SSRIs, SNRIs): monitor for increased sedation or mood changes. - Alcohol: concurrent use can exacerbate hepatic stress and CNS effects.